Compare · CRBP vs INM

CRBP vs INM

Side-by-side comparison of Corbus Pharmaceuticals Holdings Inc. (CRBP) and InMed Pharmaceuticals Inc. (INM): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CRBP and INM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • CRBP is the larger of the two at $61.9M, about 7.2x INM ($8.5M).
  • INM has been more active in the news (12 items in the past 4 weeks vs 9 for CRBP).
  • CRBP has more recent analyst coverage (10 ratings vs 1 for INM).
MetricCRBPINM
Company
Corbus Pharmaceuticals Holdings Inc.
InMed Pharmaceuticals Inc.
Price
-
-
Market cap
$61.9M
$8.5M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
News (4w)
9
12
Recent ratings
10
1
CRBP

Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

INM

InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Latest CRBP

Latest INM